Ablation versus breast-conserving surgery for early hormone receptor–positive breast cancer
Official title: Prospective, Randomized Controlled Study Comparing Cryo-Thermal Ablation With Traditional Breast-Conserving Surgery in HR-Positive, HER2-Negative Early-Stage Breast Cancer
Run by Peking University People's Hospital · NCT07484087 · Data updated 2026-11-12
This trial will test whether a minimally invasive hybrid cryo-thermal ablation works as well as breast-conserving surgery for women aged 50 and older with a single, small ER/PR-positive, HER2-negative early breast cancer.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 50 Years and up |
| Sex | Women only |
| Enrollment | 264 (estimated) |
| Sponsor | Peking University People's Hospital Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Status | Recruiting |
| Started | January 1, 2026 |
| Main results expected | December 31, 2028 |
| Study ends | December 31, 2031 |
| Registry record updated | March 19, 2026 |
| Trial ID | NCT07484087 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are women aged 50 or older with a single, ultrasound-visible invasive ductal carcinoma ≤2 cm, grade 1–2, ER/PR-positive, HER2-negative, and no clinical or radiologic lymph node involvement who agree to randomization.
✕Probably not a fit
Patients with multifocal disease, extensive intraductal component, skin or muscle invasion, prior treatment for the current cancer, or who are pregnant or breastfeeding are unlikely to benefit from this trial.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective, single-center, randomized controlled trial at Peking University People's Hospital that will randomize eligible patients 1:1 to receive hybrid cryo-thermal ablation or standard breast-conserving surgery. Eligible patients are women aged 50 or older with a unifocal invasive ductal carcinoma ≤2 cm, grade 1–2, ER/PR-positive and HER2-negative, and clinically node-negative. The hybrid device combines deep cryoablation and high-intensity heating and is applied under imaging guidance for ultrasound-visible tumors. Clinical and clinicopathological data will be collected to compare outcomes between the two groups.
Why it matters
Potential benefit: If successful, this approach could offer a less invasive treatment that preserves breast appearance while maintaining cancer control.
How similar studies have gone: Ablative techniques such as cryoablation have shown promising results in small studies, but the hybrid cryo-thermal approach is relatively novel and has not been widely compared with surgery in large randomized trials.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * 1.Age ≥50 Years 2.Unifocal disease (single tumor) confirmed by ultrasound, MRI, or mammography. Ultrasound visibility: Essential for precise intraoperative ablation targeting. 3.Pathologically Confirmed Invasive Ductal Carcinoma (IDC)。Diagnostic Method: Core needle biopsy (CNB) confirming IDC. 4.Histologic Grade: G1 or G2; ER/PR-positive and HER2-negative. 5.TNM stage: IA. Tumor Size: ≤2 cm; Lymph Node Status: Clinically \& radiologically negative (no palpable/imaging-detected axillary involvement). 6.Written consent for clinical trial participation and acceptance of random assignment Exclusion Criteria: * 1.Extensive intraductal component (EIC) suggested by imaging or pathology. 2.Invasion of adjacent skin or muscle. 3.Prior anticancer treatment for the current disease, including but not limited to chemotherapy, endocrine therapy, targeted therapy, or immunotherapy. 5.Refusal to undergo breast-conserving surgery. 6.Pregnancy or lactation. 7.Previous radiotherapy to the affected breast or other contraindications to radiotherapy. 8.Concurrent untreated malignancies or severe systemic diseases, 9.Known allergy, intolerance, or contraindications to cryotherapy (e.g., cryoglobulinemia, implanted electronic devices). 10.Inability to comply with follow-up or refusal of adjuvant therapy. 11.Vulnerable populations, including individuals with neurological disorders, cognitive impairment, or critical illness.
Where it's running
-
Peking University People's Hospital
Beijing, Beijing Municipality, China Recruiting
Study contacts
- Study coordinator: yuan peng, doctor
- Email: 13671287670@163.com
- Phone: 86+13671287670
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Gyrotonic exercise for elders with breast cancer and Behcet disease
We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.
-
PECS II vs SPSIP nerve blocks for pain after mastectomy
This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
Compare a new endoscopy-assisted breast-conserving surgery with the usual approach
This study tests whether a new endoscopy-assisted breast-conserving technique can provide similar or better cosmetic outcomes and safety compared with conventional breast-conserving surgery in women with early breast cancer who want to preserve their breast.
-
Different skin care approaches to prevent skin reactions after mastectomy radiation
This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.
-
3D Heart Strain to Detect Early Cardiotoxicity in Cancer Therapy
This study tests whether 3D echocardiography can detect early heart damage from cancer treatments like anthracyclines or HER2-targeted therapy better than standard 2D methods.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.